Advaxis, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing

NEW YORK, Jan. 28, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for Advaxis, Inc. shareholders (NASDAQ: ADXS). Concerned ADXS investors who purchased between January 7, 2015 and January 20, 2015 are encouraged to contact securities attorney Hamilton Lindley by clicking here.

The law firm's investigation will focus on potential federal securities law violations. SeekingAlpha published on January 21, 2015 an article asserting that Advaxis had misstated the tumor response data for its ADXS-HPV drug in a recent corporate presentation.  Advaxis overstated its effectiveness in shrinking tumors. The article also alleges that Advaxis misled investors concerning the design of its planned Phase 3 trial. Advaxis shares fell $3.39 per share, or over 28%, to close at $8.37 per share on January 21, 2015 upon this news. Our potential shareholder lawsuit will seek to ensure that Advaxis, Inc. works to enrich shareholders, not just the management. 

Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. ADXS stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/ADXS.  

Dunnam & Dunnam also engages in business litigation and personal injury law. 

SOURCE Dunnam & Dunnam

Related Links

http://www.dunnamlaw.com